Marksans Pharma Ltd
NSE:MARKSANS

Watchlist Manager
Marksans Pharma Ltd Logo
Marksans Pharma Ltd
NSE:MARKSANS
Watchlist
Price: 293.7 INR -0.02% Market Closed
Market Cap: 133.1B INR
Have any thoughts about
Marksans Pharma Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one MARKSANS stock under the Base Case scenario is 184.96 INR. Compared to the current market price of 293.7 INR, Marksans Pharma Ltd is Overvalued by 37%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MARKSANS Relative Value
Base Case
184.96 INR
Overvaluation 37%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

5.6
P/S
P/S
Price to Sales
5.6
vs History
1
vs Industry
32
Median 3Y
2.1
Median 5Y
1.7
Industry
2.5
Forward
4.9
More Details
38.4
P/E
P/E
Price to Earnings
38.4
vs History
1
vs Industry
17
Median 3Y
14.3
Median 5Y
12
Industry
21.8
Forward
33.9
More Details
61.4
P/OCF
P/OCF
Price to OCF
61.4
vs History
1
vs Industry
11
Median 3Y
21.3
Median 5Y
17.8
Industry
16.1
More Details
3 379.5
P/FCFE
P/FCFE
Price to FCFE
3 379.5
vs History
1
vs Industry
5
Median 3Y
30.8
Median 5Y
23.8
Industry
23.8
More Details
5.8
P/B
P/B
Price to Book Value
5.8
vs History
1
vs Industry
18
Median 3Y
2.4
Median 5Y
2.5
Industry
2.1
More Details
5.4
EV/S
EV/S
Enterprise Value to Sales
5.4
vs History
1
vs Industry
31
Median 3Y
1.7
Median 5Y
1.5
Industry
2.7
Forward
4.7
More Details
9.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.7
vs History
1
vs Industry
30
Median 3Y
3.4
Median 5Y
2.8
Industry
5.2
More Details
25.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
25.3
vs History
1
vs Industry
21
Median 3Y
9.1
Median 5Y
7.6
Industry
13.5
Forward
22.8
More Details
30.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
30.2
vs History
1
vs Industry
20
Median 3Y
10.7
Median 5Y
9
Industry
16.8
Forward
26.8
More Details
59
EV/OCF
EV/OCF
Enterprise Value to OCF
59
vs History
1
vs Industry
12
Median 3Y
18.7
Median 5Y
15.7
Industry
15.2
More Details
246.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
246.2
vs History
11
vs Industry
1
Median 3Y
32.4
Median 5Y
21.9
Industry
19.3
More Details
6.6
EV/IC
EV/IC
Enterprise Value to IC
6.6
vs History
1
vs Industry
18
Median 3Y
2.6
Median 5Y
2.6
Industry
1.9
More Details

Multiples Across Competitors

MARKSANS Competitors Multiples
Marksans Pharma Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Marksans Pharma Ltd
NSE:MARKSANS
133.1B INR 5.6 38.4 25.3 30.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
749.1B USD 18.5 89.9 48.1 53.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
348B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
150.1B USD 2.5 35.4 10.5 15.9
P/S Multiple
Revenue Growth P/S to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average P/S: 382 942.5
5.6
70%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average P/E: 33
38.4
99%
0.4
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
89.9
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.4
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average EV/EBITDA: 416.1
25.3
78%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.1
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Marksans Pharma Ltd
NSE:MARKSANS
Average EV/EBIT: 1 813.1
30.2
99%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.7
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.5
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.9
68%
0.2

See Also

Summary
MARKSANS intrinsic value, competitors valuation, and company profile.
DCF Valuation
MARKSANS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MARKSANS stock valuation using valuation multiples.
Wall Street Estimates
MARKSANS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MARKSANS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.